Sign in
COEP Stock Price, Chart, Stats & News
Coeptis Therapeutics Holdings, Inc.
Save
47.02M
Market cap
–
Current P/E
–
Forward P/E
COEP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -207.81% |
Operating margin | -956.94% |
Pretax margin | -900.72% |
Net margin | -874.29% |
Effective tax rate | 22.31% |
ROA | -60.06% |
ROE | -112.72% |
D/E | 0.02x |
Interest coverage ratio | -20.30x |
COEP valuation
P/E | – |
P/S | 27.53x |
P/B | 2.62x |
P/CF | -5.26x |
P/FCF | -4.36x |
P/OCF | -5.26x |
PEG | 0.01x |
EV multiple | -3.63x |
About
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.
Similar securities
Based on sector and market capitalization
Report issue